Titan Medical Reports Voting Results From Annual General Meeting of Shareholders

TORONTO, Ontario, July 04, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), a medical technology company, today announced the voting results from the Company’s Annual General Meeting of its shareholders held on June 30, 2023.

All of management’s nominees for election were duly elected as directors of the Company by the shareholders presented or represented by proxy at the meeting. A total of 56,441,386 of the 112,842,297 common shares outstanding, or 50.02% were voted at the meeting. The results of the vote were reported to the meeting by Computershare, which acted as scrutineer at the meeting and were as follows:

Directors	Votes For	%	Votes Withheld	%
Paul Cataford	19,958,078	71.70	7,878,054	28.30
Anthony J. Giovinazzo	21,660,514	77.81	6,175,618	22.19
Cary G. Vance	18,725,287	67.27	9,110,845	32.73
Cathy Steiner	21,982,587	78.97	5,853,546	21.03

The appointment of BDO Canada LLP as independent auditors of the Company was approved by the shareholders (with 49,752,695 votes for and 6,688,691 votes withheld) in respect of the motion.

About Titan Medical

Titan Medical Inc. (TSX: TMD; OTC: TMDIF), a medical technology company headquartered in Toronto, Ontario, has developed an expansive patent portfolio related to the enhancement of robotic assisted surgery (RAS), including through a single access point, and is currently focused on evaluating new opportunities to further develop and license its intellectual property.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to: the Company evaluating new opportunities to further develop and license its intellectual property and to generate revenue; validation of the importance and value of our patent portfolio; the Company continuing to manage its payables, and its expectation to meet its projected obligations well into 2024; the Company’s exploring opportunities for the sale of its testing and manufacturing equipment; the Company’s exploration of opportunities for a Business Combination; placement of the Company on a much stronger financial footing; and the Company’s dedication to continued shareholder engagement and the upcoming annual meeting.